Bildkälla: Stockfoto

Sprint Bioscience: Sprint Bioscience enters a VADA licensing agreement - Redeye

Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals. We will return with a more in-depth take in a research update.

Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals. We will return with a more in-depth take in a research update.
Börsvärldens nyhetsbrev
ANNONSER